• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cigarette smoking and response to inhaled corticosteroids in COPD.

作者信息

Bhatt Surya P, Anderson Julie A, Brook Robert D, Calverley Peter M A, Celli Bartolome R, Cowans Nicholas J, Crim Courtney, Martinez Fernando J, Newby David E, Vestbo Jørgen, Yates Julie C, Dransfield Mark T

机构信息

Division of Pulmonary, Allergy and Critical Care Medicine and Lung Health Center, University of Alabama at Birmingham, Birmingham, AL, USA

GlaxoSmithKline, Stockley Park, UK.

出版信息

Eur Respir J. 2018 Jan 18;51(1). doi: 10.1183/13993003.01393-2017. Print 2018 Jan.

DOI:10.1183/13993003.01393-2017
PMID:29348179
Abstract
摘要

相似文献

1
Cigarette smoking and response to inhaled corticosteroids in COPD.慢性阻塞性肺疾病（COPD）中的吸烟与吸入性糖皮质激素反应
Eur Respir J. 2018 Jan 18;51(1). doi: 10.1183/13993003.01393-2017. Print 2018 Jan.
2
Association between Inhaled Corticosteroids and Expiratory Central Airway Collapse in Smokers.吸烟者吸入性糖皮质激素与呼气期中央气道塌陷之间的关联。
Am J Respir Crit Care Med. 2021 Feb 15;203(4):518-521. doi: 10.1164/rccm.202008-3122LE.
3
COUNTERPOINT: Should an Attempt Be Made to Withdraw Inhaled Corticosteroids in All Patients With Stable GOLD 3 (30% ≤ FEV < 50% Predicted) COPD? No.反驳观点：对于所有GOLD 3级（预计FEV1为30%≤FEV1＜50%）病情稳定的慢性阻塞性肺疾病（COPD）患者，是否都应尝试停用吸入性糖皮质激素？答案是否定的。
Chest. 2018 Apr;153(4):782-784. doi: 10.1016/j.chest.2018.01.030. Epub 2018 Feb 2.
4
Quality of life and adherence to inhaled corticosteroids and tiotropium in COPD are related.慢性阻塞性肺疾病（COPD）患者的生活质量与吸入性糖皮质激素和噻托溴铵的依从性相关。
Int J Chron Obstruct Pulmon Dis. 2016 Jul 26;11:1679-88. doi: 10.2147/COPD.S107303. eCollection 2016.
5
POINT: Should an Attempt Be Made to Withdraw Inhaled Corticosteroids in All Patients With Stable GOLD 3 (30% ≤ FEV < 50% Predicted) COPD? Yes.观点：对于所有病情稳定的慢性阻塞性肺疾病全球倡议（GOLD）3级（预计第一秒用力呼气容积[FEV]占预计值的30%≤FEV＜50%）患者，是否应尝试停用吸入性糖皮质激素？是。
Chest. 2018 Apr;153(4):778-782. doi: 10.1016/j.chest.2018.01.029. Epub 2018 Feb 21.
6
Do inhaled corticosteroids slow FEV1 decline in COPD after all?吸入性糖皮质激素究竟能否减缓慢性阻塞性肺疾病（COPD）患者第一秒用力呼气容积（FEV1）的下降？
Thorax. 2004 Jun;59(6):538-9; author reply 539-40.
7
Inhaled corticosteroids: a controversial add-on treatment in COPD.吸入性糖皮质激素：慢性阻塞性肺疾病中一种存在争议的附加治疗方法。
Eur Respir J. 2010 Oct;36(4):973-4; author reply 974-5. doi: 10.1183/09031936.00078510.
8
Response to add-on inhaled corticosteroids in COPD based on airway hyperresponsiveness to mannitol.根据甘露醇诱导的气道高反应性对 COPD 患者添加吸入性皮质类固醇的反应。
Chest. 2012 Oct;142(4):919-926. doi: 10.1378/chest.11-2535.
9
Efficacy of an inhaled corticosteroid/long-acting β2-agonist combination in symptomatic COPD patients in GOLD groups B and D.
Eur Respir J. 2015 Jul;46(1):255-8. doi: 10.1183/09031936.00047115. Epub 2015 May 28.
10
Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.三联吸入治疗与吸入性皮质类固醇加长效β2-激动剂治疗慢性阻塞性肺疾病（TRILOGY）：一项双盲、平行组、随机对照试验。
Lancet. 2016 Sep 3;388(10048):963-73. doi: 10.1016/S0140-6736(16)31354-X. Epub 2016 Sep 1.

引用本文的文献

1
Chronic Obstructive Pulmonary Disease (COPD): Developments in Pharmacological Treatments.慢性阻塞性肺疾病（COPD）：药物治疗的进展
Drugs. 2025 May 20. doi: 10.1007/s40265-025-02188-8.
2
Current Smoker: A Clinical COPD Phenotype Affecting Disease Progression and Response to Therapy.当前吸烟者：一种影响疾病进展和治疗反应的慢性阻塞性肺疾病临床表型。
Am J Respir Crit Care Med. 2025 Feb 12;211(5):729-36. doi: 10.1164/rccm.202407-1379CI.
3
Benefit of dual bronchodilator therapy on exacerbations in former and current smokers with chronic obstructive pulmonary disease in real-world clinical practice: a multicenter validation study (TOReTO).
真实世界临床实践中，双重支气管扩张剂治疗对慢性阻塞性肺疾病既往和现吸烟者急性加重的获益：一项多中心验证研究（TOReTO）。
Respir Res. 2024 Oct 17;25(1):377. doi: 10.1186/s12931-024-02971-3.
4
AERIFY-1/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD.AERIFY-1/2：两项关于itepekimab用于中重度慢性阻塞性肺疾病（COPD）既往吸烟者的3期随机对照试验。
ERJ Open Res. 2024 Sep 23;10(5). doi: 10.1183/23120541.00718-2023. eCollection 2024 Sep.
5
Association of Lifestyle Behaviors with Quality of Life in Patients with COPD: A Cross-Sectional Study in Primary Care.慢性阻塞性肺疾病患者生活方式行为与生活质量的关联：一项初级保健中的横断面研究
J Clin Med. 2024 Aug 14;13(16):4793. doi: 10.3390/jcm13164793.
6
Current smoking reduces small airway eosinophil counts in COPD.当前吸烟可降低慢性阻塞性肺疾病（COPD）患者的小气道嗜酸性粒细胞计数。
ERJ Open Res. 2024 Jan 22;10(1). doi: 10.1183/23120541.00870-2023. eCollection 2024 Jan.
7
Rational use of inhaled corticosteroids for the treatment of COPD.COPD 的吸入性皮质类固醇的合理使用。
NPJ Prim Care Respir Med. 2023 Jul 24;33(1):27. doi: 10.1038/s41533-023-00347-6.
8
Asthma and Tobacco Smoking.哮喘与吸烟
J Pers Med. 2022 Jul 27;12(8):1231. doi: 10.3390/jpm12081231.
9
Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trial.慢性黏液高分泌对慢性阻塞性肺疾病患者吸入治疗反应的影响：IMPACT 试验的事后分析。
Respirology. 2022 Dec;27(12):1034-1044. doi: 10.1111/resp.14339. Epub 2022 Aug 15.
10
Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial.乌美溴铵/维兰特罗在 COPD 现吸烟者和曾吸烟者中的疗效和安全性：EMAX 试验的预先指定分析。
Adv Ther. 2021 Sep;38(9):4815-4835. doi: 10.1007/s12325-021-01855-y. Epub 2021 Aug 4.